Sol-Gel Technologies Ltd (SLGL)

$80.90 -3.08 (-3.67%)
Market Cap 233.95M
Revenue (ttm) 11.54M
Net Income (ttm) -10.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -91.68%
Debt to Equity Ratio 0.00
Volume 25,900
Avg Vol 23,758
Day's Range N/A - N/A
Shares Out 2.79M
Stochastic %K 80%
Beta 1.36
Analysts Sell
Price Target $110.00

Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 931 3433
Address:
7 Golda Meir Street, Weizmann Science Park, Ness Ziona, Israel
_Crocodileteeth
_Crocodileteeth Feb. 24 at 12:31 AM
Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 Worth swings -> $SLGL $AGAE $ARTV $RCT
0 · Reply
weichsel1
weichsel1 Feb. 23 at 6:20 PM
$SLGL With about a 230,000 share float, this stock has amazing daily volume and is very volatile, but keeps moving up.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 1:28 AM
$SLGL Current Stock Price: $83.61
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 6:04 PM
$SLGL RSI: 69.13, MACD: 5.8904 Vol: 7.21, MA20: 67.27, MA50: 56.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Invest2live
Invest2live Feb. 18 at 10:29 PM
$SLGL congrats; if you stayed long Checkout $HUMA and $GERN
0 · Reply
MaverikIT
MaverikIT Feb. 18 at 8:12 PM
@howardlindzon spec $SLGL +7.56 - headquartered in Ness Ziona, Israel. @coloradoriley
2 · Reply
ChartWalker
ChartWalker Feb. 18 at 7:59 AM
$SLGL Sol-Gel Technologies develops topical dermatology drugs, facing commercial success dependent on formulary access against entrenched treatments [citation:historical].
0 · Reply
weichsel1
weichsel1 Feb. 15 at 5:11 PM
$SLGL Back down again the next day...
0 · Reply
weichsel1
weichsel1 Feb. 13 at 1:58 AM
$SLGL anyone want to explain today ? Up 15 percent on a very down day, on basically average volume?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 9 at 3:30 PM
$SLGL Current Stock Price: $63.09
0 · Reply
Latest News on SLGL
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 7:30 AM EST - 3 months ago

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 15, 2025, 7:00 AM EDT - 6 months ago

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025, 7:15 AM EDT - 9 months ago

Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Announces Reverse Share Split

May 1, 2025, 7:00 AM EDT - 10 months ago

Sol-Gel Announces Reverse Share Split

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Apr 17, 2025, 8:40 AM EDT - 11 months ago

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

Apr 7, 2025, 10:01 AM EDT - 11 months ago

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 15, 2024, 7:00 AM EST - 1 year ago

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 17, 2024, 11:27 AM EDT - 1 year ago

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 16, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Technologies Announces Management Realignment

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Technologies Announces Management Realignment

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 20, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

May 16, 2024, 6:00 AM EDT - 1 year ago

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Nov 30, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Nov 28, 2023, 8:06 AM EST - 2 years ago

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Jun 6, 2023, 7:30 AM EDT - 2 years ago

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 20, 2023, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Mar 10, 2023, 7:00 AM EST - 3 years ago

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Jan 27, 2023, 7:29 AM EST - 3 years ago

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Jan 27, 2023, 7:00 AM EST - 3 years ago

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 4:00 AM EST - 3 years ago

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Oct 3, 2022, 8:00 AM EDT - 3 years ago

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 6:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 13, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Apr 25, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Apr 14, 2022, 8:30 AM EDT - 4 years ago

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Mar 30, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Mar 25, 2022, 11:00 AM EDT - 4 years ago

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Dec 22, 2021, 4:05 PM EST - 4 years ago

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Dec 21, 2021, 7:00 AM EST - 4 years ago

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Nov 11, 2021, 7:00 AM EST - 4 years ago

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Nov 9, 2021, 7:05 AM EST - 4 years ago

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sep 22, 2021, 7:30 AM EDT - 4 years ago

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sep 9, 2021, 8:30 AM EDT - 4 years ago

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Aug 4, 2021, 7:05 AM EDT - 4 years ago

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Jul 27, 2021, 10:26 AM EDT - 4 years ago

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Jul 27, 2021, 9:15 AM EDT - 4 years ago

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Jul 20, 2021, 7:05 AM EDT - 4 years ago

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Sol-Gel Announces Pipeline Update and Future Development Plans

Jun 28, 2021, 5:10 AM EDT - 5 years ago

Sol-Gel Announces Pipeline Update and Future Development Plans

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Jun 28, 2021, 5:00 AM EDT - 5 years ago

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

May 13, 2021, 7:05 AM EDT - 5 years ago

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX CYCN

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Apr 27, 2021, 10:02 AM EDT - 5 years ago

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

Mar 4, 2021, 7:05 AM EST - 5 years ago

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

_Crocodileteeth
_Crocodileteeth Feb. 24 at 12:31 AM
Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 Worth swings -> $SLGL $AGAE $ARTV $RCT
0 · Reply
weichsel1
weichsel1 Feb. 23 at 6:20 PM
$SLGL With about a 230,000 share float, this stock has amazing daily volume and is very volatile, but keeps moving up.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 1:28 AM
$SLGL Current Stock Price: $83.61
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 6:04 PM
$SLGL RSI: 69.13, MACD: 5.8904 Vol: 7.21, MA20: 67.27, MA50: 56.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Invest2live
Invest2live Feb. 18 at 10:29 PM
$SLGL congrats; if you stayed long Checkout $HUMA and $GERN
0 · Reply
MaverikIT
MaverikIT Feb. 18 at 8:12 PM
@howardlindzon spec $SLGL +7.56 - headquartered in Ness Ziona, Israel. @coloradoriley
2 · Reply
ChartWalker
ChartWalker Feb. 18 at 7:59 AM
$SLGL Sol-Gel Technologies develops topical dermatology drugs, facing commercial success dependent on formulary access against entrenched treatments [citation:historical].
0 · Reply
weichsel1
weichsel1 Feb. 15 at 5:11 PM
$SLGL Back down again the next day...
0 · Reply
weichsel1
weichsel1 Feb. 13 at 1:58 AM
$SLGL anyone want to explain today ? Up 15 percent on a very down day, on basically average volume?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 9 at 3:30 PM
$SLGL Current Stock Price: $63.09
0 · Reply
DORIN95
DORIN95 Jan. 28 at 10:23 PM
$SLGL back to 70 +
0 · Reply
weichsel1
weichsel1 Jan. 23 at 7:29 PM
$SLGL about a 30 percent swing in trading range today. 48 to 63. Talk about volatility
0 · Reply
weichsel1
weichsel1 Jan. 22 at 3:26 PM
$SLGL no trades today at all…wacky
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 21 at 12:37 PM
$SLGL activated 4.31 filler for markets old $SINT * open ing up the 29-32 pt channel for markets
0 · Reply
weichsel1
weichsel1 Jan. 14 at 7:14 PM
$SLGL any news driving this surge?
0 · Reply
weichsel1
weichsel1 Jan. 14 at 3:31 AM
$SLGL 36 percent jump in five trading days
0 · Reply
TorvexGHJ
TorvexGHJ Jan. 13 at 7:08 PM
$SLGL biotech under the radar, quiet accumulation, squeeze risk if volume ignition hits
0 · Reply
weichsel1
weichsel1 Jan. 8 at 4:12 PM
$SLGL There is actual stable trading at this new higher price level - not just a blip of bid / ask flux.
0 · Reply
DarkSonar
DarkSonar Jan. 7 at 11:23 PM
$SLGL Remember two years ago there was this gentleman here buying up these shares and he was the only person talking about this stock (I was here trying to get a position) and he talked about the future of this stock. It went parabolic. They reversed split and now is $53.00. I think he was loading up at $0.60s My hats off to him if he’s still here. 💎
1 · Reply
kshonstocks
kshonstocks Jan. 7 at 6:56 PM
$SLGL 99 rs name https://research.investors.com/stock-quotes/nasdaq-solgel-technologies-slgl.htm
0 · Reply
GianniCisnerosVp
GianniCisnerosVp Jan. 7 at 5:45 AM
$SLGL thin tape biotech vibe, coil is tight, volume igniti
0 · Reply
weichsel1
weichsel1 Jan. 1 at 3:24 AM
$SLGL up 10 percent after hours? Is someone playing with the year closing price?
1 · Reply